Upcoming 50 pharma manufacturing plants under PLI scheme to be completed in 2 years: Centre
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-09-28 11:22 GMT | Update On 2024-09-28 11:22 GMT
New Delhi: The Centre has informed that the 50 upcoming pharmaceutical manufacturing plants under the production-linked incentive (PLI) scheme will be completed within the next two years. Dr. Arunish Chawla, Secretary of the Department of Pharmaceuticals, stated that over 50 new greenfield manufacturing facilities for pharmaceuticals and medical devices have already been completed.
At the annual pharma summit 2024 organised by industry chamber Assocham, he said, “The PLI plants have catalysed $10 billion in exports from India to countries with the highest regulatory standards.”
“Many reforms have been done in both the regulatory framework and in the schemes. We are working very hard to upgrade the quality framework for all pharma and drug units. We want to make India not just a pharmacy of the world, but a reliable pharmacy of the world,” the Secretary emphasised.
The all-big pharma companies, global and multinational companies are now expanding their footprint and their business in India and also locating their value chains here, he added.
Also, a huge number of contract research manufacturing and development organisations (CRDMO) are coming up in the country.
According to IANS, Chawla said that we are moving from the generics to the biosimilar space.
“We are the third largest producer of drugs and pharmaceuticals by volume. Drugs and pharma and Meditech are the fourth largest merchandise export from India. Nine out of top 25 generic firms are located in India. And going forward, our contribution to humankind will increase,” said Chawla.
Last year, more than 50 per cent of the drug and pharma produced in the country was exported.
In the closing year, in the surgical and consumable space, the Indian Meditech industry exported more than what the country imported. In other rising sunrise sectors like imaging devices, body implants, in vitro diagnostics (IVDs), achieved double digit growth and exports grew more than double digits.
The Secretary mentioned that from April to August, the pharma and Meditech has become the fourth largest manufacturing export from India.
Ishteyaque Amjad, Chair, Assocham Pharma and Biotech Council, emphasised the need for affordable medicines while maintaining high standards at the event.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.